Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience.

@article{Saber2007PosttransplantationCT,
  title={Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience.},
  author={Luciana Tanajura Saber and Masataka Ikeda and Joana Alexandra De Almeida},
  journal={Transplantation proceedings},
  year={2007},
  volume={39 10},
  pages={
          3098-100
        }
}
Sirolimus (SRL) has become an option in kidney transplantation, especially among patients who develop chronic allograft nephropathy (CAN). This study sought to evaluate the safety and efficacy of SRL in 103 kidney recipients of mean age 40 years, including 78 recipients of organs from deceased donors. The major reason for conversion was calcineurin inhibitor (CNI) nephrotoxicity (42.3%) followed by CAN (35.4%). A preconversion kidney biopsy was performed in 89 patients with CAN diagnosed in 51… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Tuberculosis prevalence in renal transplant recipients: systematic review and meta-analysis.

  • Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
  • 2013

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

  • Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • 2011

Reactivation of tuberculosis during temsirolimus therapy

  • Investigational New Drugs
  • 2010
VIEW 1 EXCERPT
CITES BACKGROUND